HC Wainwright Brokers Lower Earnings Estimates for FDMT

Key Points

• HC Wainwright has lowered its Q3 2025 EPS estimates for 4D Molecular Therapeutics from ($0.92) to ($1.01), reflecting a less optimistic outlook for the company’s earnings.
• The current consensus estimates suggest that 4D Molecular Therapeutics will report a full-year loss of ($2.84) per share for 2023, with predicted losses increasing in subsequent years.
• Despite negative earnings performance, the company's stock price recently increased by 8.5% and has received mixed ratings from analysts, including several "buy" ratings and one "sell".

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Research analysts at HC Wainwright lowered their Q3 2025 earnings per share (EPS) estimates for shares of 4D Molecular Therapeutics in a note issued to investors on Tuesday, August 12th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($1.01) for the quarter, down from their prior forecast of ($0.92). The consensus estimate for 4D Molecular Therapeutics' current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for 4D Molecular Therapeutics' Q4 2025 earnings at ($1.05) EPS, FY2025 earnings at ($3.90) EPS, FY2026 earnings at ($4.22) EPS, FY2027 earnings at ($4.82) EPS, FY2028 earnings at ($5.00) EPS and FY2029 earnings at ($3.88) EPS.

FDMT has been the subject of a number of other research reports. Roth Capital lowered their price objective on 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research note on Tuesday. Weiss Ratings reiterated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research report on Tuesday, July 29th. Barclays decreased their target price on 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. The Goldman Sachs Group decreased their target price on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Finally, Chardan Capital reiterated a "buy" rating and issued a $25.00 target price on shares of 4D Molecular Therapeutics in a research report on Tuesday. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, 4D Molecular Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $30.40.

4D Molecular Therapeutics Stock Up 8.5%

Shares of NASDAQ FDMT opened at $6.67 on Thursday. 4D Molecular Therapeutics has a fifty-two week low of $2.23 and a fifty-two week high of $17.41. The business has a 50 day moving average price of $4.56 and a two-hundred day moving average price of $4.11. The firm has a market cap of $308.99 million, a PE ratio of -1.89 and a beta of 2.83.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.98) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.52 million.

Institutional Trading of 4D Molecular Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Federated Hermes Inc. lifted its holdings in shares of 4D Molecular Therapeutics by 33.4% in the 2nd quarter. Federated Hermes Inc. now owns 1,667,338 shares of the company's stock worth $6,186,000 after purchasing an additional 417,157 shares during the last quarter. Marshall Wace LLP increased its position in shares of 4D Molecular Therapeutics by 62.8% during the 2nd quarter. Marshall Wace LLP now owns 257,620 shares of the company's stock valued at $956,000 after purchasing an additional 99,332 shares during the period. Invesco Ltd. increased its position in shares of 4D Molecular Therapeutics by 19.2% during the 2nd quarter. Invesco Ltd. now owns 140,325 shares of the company's stock valued at $521,000 after purchasing an additional 22,557 shares during the period. Norges Bank acquired a new position in shares of 4D Molecular Therapeutics during the 2nd quarter valued at $201,000. Finally, Quadrature Capital Ltd acquired a new position in shares of 4D Molecular Therapeutics in the 2nd quarter worth $42,000. Institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.